<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115960</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 063</org_study_id>
    <secondary_id>10058</secondary_id>
    <nct_id>NCT00115960</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Gag DNA Vaccine Alone or With IL-15 DNA, Boosted With HIV-1 Gag DNA + IL-15 DNA or HIV-1 Gag DNA + IL-12 DNA, in Healthy, HIV-1 Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of and immune response to an&#xD;
      experimental HIV vaccine, HIV-1 gag DNA, with and without an IL-15 DNA adjuvant (at&#xD;
      escalating doses of 100, 500, and 1500 mcg). This study will also test the safety of and&#xD;
      immune response to the HIV-1 gag DNA vaccine plus IL-15 DNA adjuvant given with or without 2&#xD;
      other adjuvant-containing booster vaccines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HIV epidemic is a major global health challenge, causing tremendous human suffering and&#xD;
      economic loss throughout the world. The need for a safe, effective, and affordable HIV&#xD;
      preventive vaccine is critical. This 2-part study will determine the safety and&#xD;
      immunogenicity of the experimental HIV vaccine HIV-1 gag DNA with or without IL-15 adjuvant,&#xD;
      boosted with either the HIV-1 gag DNA and IL-15 adjuvant vaccine or the HIV-1 gag DNA and&#xD;
      IL-12 adjuvant vaccine.&#xD;
&#xD;
      There are two parts to this study. Part A will last 12 months. In Part A, 48 participants&#xD;
      will be randomly assigned to 1 of 4 groups in sequential order (dose escalation). All&#xD;
      participants will receive 3 vaccinations. Group 1 will receive 3 vaccinations of the HIV-1&#xD;
      gag DNA vaccine or placebo. Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA&#xD;
      vaccine with a low dose of IL-15 adjuvant or a placebo. Group 3 will receive 3 vaccinations&#xD;
      of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant or a placebo. Group 4&#xD;
      will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15&#xD;
      adjuvant or a placebo. Vaccinations will be given at Months 0, 1, and 3. There will be 11&#xD;
      study visits in Part A. A physical exam, pregnancy prevention counseling, medication history,&#xD;
      and adverse event reporting will occur at most visits. Urine and blood collection will occur&#xD;
      at some visits. Participants will also be asked to complete questionnaires at certain visits.&#xD;
&#xD;
      Part B will last 15 months. In Part B, 72 participants will be randomly assigned to 1 of 2&#xD;
      groups. All Part B participants will receive 5 vaccinations. Group 5 will receive 5&#xD;
      vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA or placebo; the vaccinations will&#xD;
      occur at Months 0, 1, 3, 6, and 9. Group 7 will receive 3 vaccinations of the HIV-1 gag&#xD;
      vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2&#xD;
      vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive&#xD;
      placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15&#xD;
      adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be&#xD;
      given at Months 6 and 9. There will be 13 study visits in Part B. A physical exam, pregnancy&#xD;
      prevention counseling, medication history, and adverse event reporting will occur at most&#xD;
      visits. Urine and blood collection will occur at some visits. Participants will also be asked&#xD;
      to complete questionnaires at certain visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic reactogenicity signs and symptoms, as assessed after each injection</measure>
    <time_frame>12 months postinjection for Part A, and 15 months after the first injection in Part B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measures of safety, as assessed after each injection</measure>
    <time_frame>12 months postinjection for Part A, and 15 months after the first injection in Part B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse and serious adverse experiences, as assessed after each injection</measure>
    <time_frame>12 months postinjection for Part A, and 15 months after the first injection in Part B</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-specific cellular responses by IFN-gamma ELISpot</measure>
    <time_frame>12 months postinjection for Part A, and 15 months after the first injection in Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV binding antibody by ELISA</measure>
    <time_frame>12 months postinjection for Part A, and 15 months after the first injection in Part B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social impact variables</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 gag DNA</intervention_name>
    <description>DNA vaccine containing the HIV gene gag</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-15 DNA adjuvant</intervention_name>
    <description>Cytokine injection</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-12 DNA adjuvant</intervention_name>
    <description>Cytokine injection</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Note: Group 6 has been removed from Part B of the protocol as of the 04/11/06 amendment.&#xD;
        Because a regimen similar to Group 6's regimen is being tested in HVTN 060, the vaccine&#xD;
        manufacturer decided that Group 6's regimen was not a priority for testing.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV uninfected&#xD;
&#xD;
          -  Access to a participating HIV Vaccine Trials Unit (HVTU)&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  Willing and able to comply with all study requirements&#xD;
&#xD;
          -  In good general health&#xD;
&#xD;
          -  Willing to use acceptable methods of contraception for at least 21 days prior to study&#xD;
             entry and until the last study visit. More information about this criterion can be&#xD;
             found in the protocol.&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Anti-hepatitis C virus (anti-HCV) antibody negative or negative HCV PCR if anti-HCV&#xD;
             antibody is positive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV vaccines in prior HIV vaccine trial&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to first vaccination&#xD;
&#xD;
          -  Blood products within 120 days prior to first vaccination&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to first vaccination&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to first vaccination&#xD;
&#xD;
          -  Investigational research agents within 30 days prior to first vaccination&#xD;
&#xD;
          -  Medically indicated subunit or killed vaccines within 14 days prior to first study&#xD;
             vaccine administration, or allergy treatment with antigen injections within 30 days&#xD;
             prior to first vaccination&#xD;
&#xD;
          -  Current tuberculosis (TB) prophylaxis or therapy&#xD;
&#xD;
          -  Clinically significant medical condition, physical exam findings, abnormal laboratory&#xD;
             results, or past medical history with clinically significant implications for current&#xD;
             health&#xD;
&#xD;
          -  Any medical, psychiatric, or social condition that, in the opinion of the&#xD;
             investigator, may interfere with the study&#xD;
&#xD;
          -  Any occupational or other responsibility that, in the opinion of the investigator, may&#xD;
             interfere with the study&#xD;
&#xD;
          -  Diagnosis of allergy to amide-type local anesthetics&#xD;
&#xD;
          -  Serious adverse reaction to vaccines, including anaphylaxis and related symptoms such&#xD;
             as hives, respiratory difficulty, angioedema, or abdominal pain. A person who had an&#xD;
             adverse reaction to pertussis vaccine as a child is not excluded.&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Unstable asthma&#xD;
&#xD;
          -  Diabetes mellitus Type 1 or Type 2. Participants with histories of isolated&#xD;
             gestational diabetes are not excluded.&#xD;
&#xD;
          -  Thyroid disease requiring treatment in the past 12 months&#xD;
&#xD;
          -  Serious angioedema within the last 3 years&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Body mass index (BMI) of 40 or greater OR BMI of 35 or greater, when certain other&#xD;
             criteria are met. More information about these criteria can be found in the protocol.&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Cancer. Participants with surgically removed cancer that, in the opinion of the&#xD;
             investigator, is unlikely to recur are not excluded.&#xD;
&#xD;
          -  Seizure disorder requiring medication within the past 3 years&#xD;
&#xD;
          -  Absence of the spleen&#xD;
&#xD;
          -  Psychiatric condition, including psychoses within the past 3 years, ongoing risk for&#xD;
             suicide, or history of suicide attempt or gesture within the past 3 years&#xD;
&#xD;
          -  Pregnant or breastfeeding, or plan to become pregnant during the study&#xD;
&#xD;
        Exclusion Criteria for Part B Participants:&#xD;
&#xD;
          -  Diagnosis of allergy to egg products&#xD;
&#xD;
          -  Diagnosis of allergy to yeast-derived products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Baden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xia Jin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Blood Ctr./Bronx CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Blood Ctr./Union Square CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Prevention &amp; Treatment CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester HVTN CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital's HVTU</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sao Paulo HVTU - CRT DST/AIDS CRS</name>
      <address>
        <city>San Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information on preventive HIV vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1559</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Boyer JD, Chattergoon M, Muthumani K, Kudchodkar S, Kim J, Bagarazzi M, Pavlakis G, Sekaly R, Weiner DB. Next generation DNA vaccines for HIV-1. J Liposome Res. 2002 Feb-May;12(1-2):137-42. Review.</citation>
    <PMID>12604047</PMID>
  </reference>
  <reference>
    <citation>Stratov I, DeRose R, Purcell DF, Kent SJ. Vaccines and vaccine strategies against HIV. Curr Drug Targets. 2004 Jan;5(1):71-88. Review.</citation>
    <PMID>14738219</PMID>
  </reference>
  <reference>
    <citation>Xin KQ, Hamajima K, Sasaki S, Tsuji T, Watabe S, Okada E, Okuda K. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine. 1999 Feb 26;17(7-8):858-66.</citation>
    <PMID>10067692</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 26, 2005</study_first_submitted>
  <study_first_submitted_qc>June 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2005</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL-12</keyword>
  <keyword>IL-15</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

